Compare Amgen, Inc. (AMGN) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs SkyWest Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while SkyWest Inc trades at $99.72 (market cap $3.96B). The key difference: Amgen, Inc. is far larger — about 49.5× SkyWest Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| AMGN | SKYW | |
|---|---|---|
Market Cap | $196.12B | $3.96B |
Sector | Health | Technology |
52-Week High | $388.16 | $123.72 |
52-Week Low | $271.18 | $78.40 |
Enterprise Value | $241.41B | $5.81B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
SkyWest (SKYW) trades at $99.72, down 0.29% on the day, with strong technical momentum showing bullish moving averages and key support at $98. The company maintains solid fundamentals with a P/E of 9.57, net income margin of 10.42%, and consistent earnings beats in recent quarters. Recent leadership changes include Wade Steel's promotion to President and COO of SkyWest Airlines.
SkyWest presents attractive valuation with upside to the $109.33 consensus price target, supported by strong analyst sentiment (56% buy ratings). Key risks include rising fuel costs highlighted in recent government data showing 84% year-over-year increases, which could pressure airline profitability despite current operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
